Table 2

Patients’ evolution during follow-up: hemoglobin, renal biomarkers and clinical outcomes
Variables Control EPO 20’000ui EPO 40’000ui P*
Median (25th-75thpercentiles) N = 40 N = 20 N = 20
Hemoglobin R g/l 97.5 (87.5-105.8) 100.5 (92.3-107) 98 (85–107) 0.41
Hemoglobin last g/l 100.5 (96.3-113.8) 100.0 (93–109) 101.5 (90.8-114.8) 0.69
Renal biomarkers
Creatinine R μmol/l 78 (61–98) 94 (74.5-102) 91.5 (67.8-114.3) 0.29
Creatinine 48 h μmol/l 79 (65.8-88.8) 78 (62–98) 82.5 (66–114.5) 0.23
Creatinine 96 h μmol/l 77.5 (63.3-85.8) 75 (65–92) 87 (72.8-100.8) 0.53
Cystatine C Rmg/l 1.1 (0.9-1.4) 1.2 (1.1-1.5) 1.2 (1.0-1.4) 0.60
Cystatine C 48 h - mg/l 1.2 (1.1-1.4) 1.3 (1.1-1.6) 1.3 (1.1-1.6) 0.25
Cystatine C 96 h mg/l 1.3 (1.1-1.4) 1.2 (1.1-1.5) 1.3 (1.1-1.7) 0.80
Urinary Ngal R ng/ml 21 (5.7-44.3) 43.3 (18.3-62.9) 11 (0–76) 0.18
Urinary Ngal 48 h ng/ml 26.8 (12–46.7) 15.7 (2.6-39) 26 (6.2-58.8) 0.47
Clinical outcomes
Hospital stay in days 14.5 (11–21.8) 16.5 (10.8- 26.8) 15.5 (10.3-22.5) 0.96
ICU stay in days 1 (1–3) 2.5 (1.3- 5) 1 (1–3.8) 0.07
Acute Kidney Injury ¤ 7 (17.5%) 5 (25%) 6 (30%) 0.53
Death 2 (5%) 1 (5%) 2 (10%) 0.74

*p compares the 3 treatment groups.

R: randomization. 48 h: 48 hours after randomization. 96 h: 96 hours after randomization. ICU: Intensive care Unit.

¤ In stage 1: n = 15; in stage 2: n = 3 (n = 2 in EPO 40’000 and n = 1 in EPO 20’000 groups).

de Seigneux et al.

de Seigneux et al. BMC Nephrology 2012 13:132   doi:10.1186/1471-2369-13-132

Open Data